Understanding Creutzfeldt-Jackob disease from a viewpoint of amyloidogenic evolvability

References

• Appleby BS , Lyketsos CG. Rapidly progressive dementias and the treatment of human prion diseases. Expert Opin Pharmacother. 2011;12:1–12.
   PubMed Web of Science ®Google Scholar
• Maltete D , Guyant-Marechal L , Mihout B , et al. Movement disorders and Creutzfeldt-Jakob disease: a review. Parkinsonism Relat Disord. 2006;12:65–71.
   PubMed Web of Science ®Google Scholar
• Zerr I , Hermann P. Diagnostic challenges in rapidly progressive dementia. Expert Rev Neurother. 2018;18:761–772.
   PubMed Web of Science ®Google Scholar
• Prusiner SB . Biology and genetics of prions causing neurodegeneration. Annu Rev Genet. 2013;47:601–623.
   PubMed Web of Science ®Google Scholar
• Iwasaki Y . Creutzfeldt-Jakob disease. Neuropathology. 2017;37:174–188.
   PubMed Web of Science ®Google Scholar
• Morales R , Moreno-Gonzalez I , Soto C . Cross-seeding of misfolded proteins: implications for etiology and pathogenesis of protein misfolding diseases. PLoS Pathog. 2013;9:e1003537.
   PubMed Web of Science ®Google Scholar
• Ferrer I , Blanco R , Carmona M , et al. Prion protein expression in senile plaques in Alzheimer’s disease. Acta Neuropathol. 2001;101:49–56.
   PubMed Web of Science ®Google Scholar
• Haik S , Privat N , Adjou KT , et al. Alpha-synuclein-immunoreactive deposits in human and animal prion diseases. Acta Neuropathol. 2002;103:516–520.
   PubMed Web of Science ®Google Scholar
• Hashimoto M , Ho G , Takamatsu Y , et al. Evolvability and neurodegenerative disease: antagonistic pleiotropy phenomena derived from amyloid aggregates. J Parkinson’s Dis. 2018;8:405–408.
   PubMedGoogle Scholar
• Kovacs GG , Zerbi P , Voigtlander T , et al. The prion protein in human neurodegenerative disorders. Neurosci Lett. 2002;329:269–272.
   PubMed Web of Science ®Google Scholar
• Rossi M , Kai H , Baiardi S , et al. The characterization of AD/PART co-pathology in CJD suggests independent pathogenic mechanisms and no cross-seeding between misfolded Abeta and prion proteins. Acta Neuropathol Commun. 2019;7:53.
   PubMed Web of Science ®Google Scholar
• Hashimoto M , Ho G , Takamatsu Y , et al. Possible role of amyloid cross-seeding in evolvability and neurodegenerative disease. J Parkinsons Dis. 2019;9:793–802.
   PubMedGoogle Scholar
• Hashimoto M , Ho G , Sugama S , et al. Evolvability of amyloidogenic proteins in human brain. J Alzheimer’s Dis. 2018;62:73–83.
   PubMed Web of Science ®Google Scholar
• Takamatsu Y , Ho G , Waragai M , et al. Transgenerational interaction of Alzheimer’s disease with schizophrenia through amyloid evolvability. J Alzheimers Dis. 2019;68:473–481.
   PubMed Web of Science ®Google Scholar
• Cong X , Casiraghi N , Rossetti G , et al. Role of prion disease-linked mutations in the intrinsically disordered N-terminal domain of the prion protein. J Chem Theory Comput. 2013;9:5158–5167.
   PubMed Web of Science ®Google Scholar
• Takamatsu Y , Fujita M , Ho GJ , et al. Motor and nonmotor symptoms of parkinson’s disease: antagonistic pleiotropy phenomena derived from alpha-synuclein evolvability? Parkinsons Dis. 2018;(2018):5789424.
   PubMed Web of Science ®Google Scholar
• Pham N , Akonasu H , Shishkin R , et al. Plasma soluble prion protein, a potential biomarker for sport-related concussions: a pilot study. PLoS One. 2015;10:e0117286.
   PubMed Web of Science ®Google Scholar
• Castilla J , Brun A , Diaz-San Segundo F , et al. Vertical transmission of bovine spongiform encephalopathy prions evaluated in a transgenic mouse model. J Virol. 2005;79:8665–8668.
   PubMed Web of Science ®Google Scholar
• Kessels HW , Nguyen LN , Nabavi S , et al. The prion protein as a receptor for amyloid-beta. Nature. 2010;466:E3–4. discussion E4-5.
   PubMed Web of Science ®Google Scholar
• Urrea L , Ferrer I , Gavin R , et al. The cellular prion protein (PrP(C)) as neuronal receptor for alpha-synuclein. Prion. 2017;11:226–233.
   PubMed Web of Science ®Google Scholar
• Aulic S , Masperone L , Narkiewicz J , et al. alpha-synuclein amyloids hijack prion protein to gain cell entry, facilitate cell-to-cell spreading and block prion replication. Sci Rep. 2017;7:10050.
   PubMed Web of Science ®Google Scholar
• Shirasaka M , Kuwata K , Honda R . alpha-Synuclein chaperone suppresses nucleation and amyloidogenesis of prion protein. Biochem Biophys Res Commun. 2020;521:259–264.
   PubMed Web of Science ®Google Scholar
• Parkin ET , Watt NT , Hussain I , et al. Cellular prion protein regulates beta-secretase cleavage of the Alzheimer’s amyloid precursor protein. Proc Natl Acad Sci U S A. 2007;104:11062–11067.
   PubMed Web of Science ®Google Scholar
• Brown P , Jannotta F , Gibbs CJ Jr. , et al. Coexistence of Creutzfeldt-Jakob disease and Alzheimer’s disease in the same patient. Neurology. 1990;40:226–228.
   PubMed Web of Science ®Google Scholar
• Powers JM , Liu Y , Hair LS , et al. Concomitant Creutzfeldt-Jakob and Alzheimer diseases. Acta Neuropathol. 1991;83:95–98.
   PubMed Web of Science ®Google Scholar
• Muramoto T , Kitamoto T , Koga H , et al. The coexistence of Alzheimer’s disease and Creutzfeldt-Jakob disease in a patient with dementia of long duration. Acta Neuropathol. 1992;84:686–689.
   PubMed Web of Science ®Google Scholar
• Vital A , Canron MH , Gil R , et al. A sporadic case of Creutzfeldt-Jakob disease with beta-amyloid deposits and alpha-synuclein inclusions. Neuropathology. 2007;27:273–277.
   PubMed Web of Science ®Google Scholar
• Haraguchi T , Terada S , Ishizu H , et al. Coexistence of Creutzfeldt-Jakob disease, Lewy body disease, and Alzheimer’s disease pathology: an autopsy case showing typical clinical features of Creutzfeldt-Jakob disease. Neuropathology. 2009;29:454–459.
   PubMed Web of Science ®Google Scholar
• Amouyel P , Vidal O , Launay JM , et al. The apolipoprotein E alleles as major susceptibility factors for Creutzfeldt-Jakob disease. The French research group on epidemiology of human spongiform encephalopathies. Lancet. 1994;344:1315–1318.
   PubMed Web of Science ®Google Scholar
• Campana V , Zentilin L , Mirabile I , et al. Development of antibody fragments for immunotherapy of prion diseases. Biochem J. 2009;418:507–515.
   PubMed Web of Science ®Google Scholar
• Roettger Y , Du Y , Bacher M , et al. Immunotherapy in prion disease. Nat Rev Neurol. 2013;9:98–105.
   PubMed Web of Science ®Google Scholar
• Hashimoto M , Rockenstein E , Mante M , et al. beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron. 2001;32:213–223.
   PubMed Web of Science ®Google Scholar
• Jensen PH , Hojrup P , Hager H , et al. Binding of Abeta to alpha- and beta-synucleins: identification of segments in alpha-synuclein/NAC precursor that bind Abeta and NAC. Biochem J. 1997;323((Pt 2)):539–546.
   PubMedGoogle Scholar